NOVARTIS ACQUIRES MARKETING RIGHTS OF NEW VACCINE

Swiss pharmaceutical giant Novartis AG Tuesday announced that it was acquiring the marketing and distribution rights for IC51, a new vaccine in phase three trials, from Austria's Intercell AG. As per the terms of the deal, Novartis will make an equity investment worth €30 million in the Austrian company.

Newratings (http://www.newratings.com/analyst_news/article_1296099.html)